Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06109181 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
A Phase 1 study of Arrhythmogenic Cardiomyopathy and PKP2-ACM, sponsored by Lexeo Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 5
- Study locations
NCT06109181 is a Phase 1 study of Arrhythmogenic Cardiomyopathy and PKP2-ACM that is active but no longer recruiting, run by Lexeo Therapeutics. The registered enrollment target is 10 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT06109181, a Phase 1 study of Arrhythmogenic Cardiomyopathy and PKP2-ACM, is active but no longer recruiting, sponsored by Lexeo Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM
Conditions Studied
Interventions
- GENETIC LX2020
Study Locations (5)
California
- Stanford University - Stanford
Maryland
- Johns Hopkins University - Baltimore
Michigan
- University of Michigan - Ann Arbor
New York
- University of Rochester - Rochester
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-02-29 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06109181
The ClinicalTrials.gov registry entry for NCT06109181 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexeo Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Arrhythmogenic Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which LX2020 is the first listed.
NCT06109181 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT06109181 about?
NCT06109181 is a clinical study titled "Gene Therapy for ACM Due to a PKP2 Pathogenic Variant". This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM
What is the current status of trial NCT06109181?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-02-29. Estimated completion is 2027-03.
What conditions does trial NCT06109181 study?
This clinical trial studies the following conditions: Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC.
What interventions are being tested in trial NCT06109181?
The interventions under investigation include: LX2020 (GENETIC).
Who is sponsoring clinical trial NCT06109181?
This trial is sponsored by Lexeo Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06109181 being conducted?
This trial has 5 study locations across California, Maryland, Michigan, New York, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arrhythmogenic Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.